Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

2018 Zytiga Drug Analysis: A Small Molecule Oral Irreversible Inhibitor of the 17 alpha-hydroxylase Enzyme by Johnson & Johnson - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Drug Analysis: Zytiga" drug pipelines has been added to ResearchAndMarkets.com's offering.

Zytiga (abiraterone acetate; Johnson & Johnson/AstraZeneca) is a small molecule oral irreversible inhibitor of the 17 alpha-hydroxylase enzyme which catalyzes the hydroxylation of intermediates involved in testosterone synthesis. Prostate cancer cell growth is commonly driven by hormones, and as Zytiga inhibits the rate-limiting enzyme in androgen synthesis, it blocks testosterone production activity in the testes, adrenal glands, and prostate, while preserving adrenal sufficiency.

Market Data

List of Figures

Figure 1: Zytiga for prostate cancer - SWOT analysis

Figure 2: Drug assessment summary of Zytiga for prostate cancer

Figure 3: Drug assessment summary of Zytiga for prostate cancer

Figure 4: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Zytiga drug profile

Table 2: Zytiga Phase III data in prostate cancer

Table 3: Zytiga Phase III trials in prostate cancer

Table 4: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/hkwd8d/2018_zytiga_drug?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005574/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.